Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/11/2494 |
id |
doaj-6c3d8988567c470ebe95a3809bd25958 |
---|---|
record_format |
Article |
spelling |
doaj-6c3d8988567c470ebe95a3809bd259582020-11-25T04:09:46ZengMDPI AGCells2073-44092020-11-0192494249410.3390/cells9112494Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate CancerWout Devlies0Markus Eckstein1Alessia Cimadamore2Gaëtan Devos3Lisa Moris4Thomas Van den Broeck5Rodolfo Montironi6Steven Joniau7Frank Claessens8Thomas Gevaert9Department of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Pathology, Friedrich-Alexander-University of Erlangen-Nürnberg, 91054 Erlangen, GermanySection of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, 60121 Ancona, ItalyDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumSection of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, 60121 Ancona, ItalyDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumLaboratory of Molecular Endocrinology, KU Leuven, 3000 Leuven, BelgiumDepartment of Pathology, University Hospitals Leuven, 3000 Leuven, BelgiumThe development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.https://www.mdpi.com/2073-4409/9/11/2494prostate cancerbiomarkertargeted therapieshistologymCRPCandrogen receptor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wout Devlies Markus Eckstein Alessia Cimadamore Gaëtan Devos Lisa Moris Thomas Van den Broeck Rodolfo Montironi Steven Joniau Frank Claessens Thomas Gevaert |
spellingShingle |
Wout Devlies Markus Eckstein Alessia Cimadamore Gaëtan Devos Lisa Moris Thomas Van den Broeck Rodolfo Montironi Steven Joniau Frank Claessens Thomas Gevaert Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer Cells prostate cancer biomarker targeted therapies histology mCRPC androgen receptor |
author_facet |
Wout Devlies Markus Eckstein Alessia Cimadamore Gaëtan Devos Lisa Moris Thomas Van den Broeck Rodolfo Montironi Steven Joniau Frank Claessens Thomas Gevaert |
author_sort |
Wout Devlies |
title |
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer |
title_short |
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer |
title_full |
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer |
title_fullStr |
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer |
title_full_unstemmed |
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer |
title_sort |
clinical actionability of the genomic landscape of metastatic castration resistant prostate cancer |
publisher |
MDPI AG |
series |
Cells |
issn |
2073-4409 |
publishDate |
2020-11-01 |
description |
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data. |
topic |
prostate cancer biomarker targeted therapies histology mCRPC androgen receptor |
url |
https://www.mdpi.com/2073-4409/9/11/2494 |
work_keys_str_mv |
AT woutdevlies clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT markuseckstein clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT alessiacimadamore clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT gaetandevos clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT lisamoris clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT thomasvandenbroeck clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT rodolfomontironi clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT stevenjoniau clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT frankclaessens clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer AT thomasgevaert clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer |
_version_ |
1724421861464342528 |